Please assess the completion status of the following clinical trial:

Trial Title: Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have an age range between 18 to 65 years (inclusive).~2. Patients with fatty liver confirmed by ultrasound.~3. Patients must meet the criteria for impaired glucose regulation or type 2 diabetes mellitus (FPG ≥ 5.6 mmol/L and/or a two hour glucose value ≥ 7.8 mmol/L).~4. Course of diabetic mellitus no more than 1 years~5. Diabetic patients have not received anti-diabetic drugs, including insulin, biguanides, sulfonylureas, thiazolidinediones, Alpha-glucosidase inhibitors, or glinides for 4 weeks before the time of enrollment~6. Patients have not received lipid-regulating drugs (statins, fibrates)for 4 weeks before the time of enrollment~7. Blood pressure \< 160/100 mmHg,after receiving lifestyle therapy and effective anti-hypertensive drugs.~8. Patients must stopped other drugs medications for four weeks prior to entering the treatment period, such as: silybin, ursodeoxycholic acid, Polyene Phosphatidylcholine, vitamin E, some herbs with effect of regulating lipid and protecting liver function, etc.~9. Liver fat content(LFC) assessed by 1H MRS ≥ 13%(LFC was calculated by dividing the integral of the methylene groups in fatty acid chains of the hepatic triglycerides by the sum of methylene groups and water).~Exclusion Criteria:~1. Any causes of chronic liver disease other than NAFLD (such as - but not restricted to - alcohol or drug abuse, medication, chronic hepatitis B or C, autoimmune, etc.);~2. Patients with significantly impaired liver function: ALT or AST ≥ 2 times upper limit of normal;~3. HBsAg (+) and/or HCV-Ab (+);~4. Patients with type 1 diabetes mellitus or gestational diabetes or special type diabetes, and patients with BMI \< 22 Kg/m2;~5. Course of diabetes more than 1 years;~6. Diabetics patients who have taken or are taking oral glucose-lowering drugs or insulin;~7. Diabetics patients with a HbA1c \> 7.5% on initial visit;~8. Patients with severe diabetes complications (diabetes ketoacidosis, diabetes coma or with symptomatic of diabetes coma; dysfunction of nerve, retinopathy, dysfunction of kidney）;~9. Patients with serum creatinine ≥ 1.5 mg/dL (133 umol/L);~10. Patients with a history of clinically significant heart disease (myocardial infarct, heart failure, and or severe cardiac rhythm);~11. Complicating severe infection, within 6 months after operation, severe trauma;~12. Patients with excess alcohol consumption≥140g/week(male); ≥ 70g/week(female);~13. Patients have participated other clinical trials within 24 weeks;~14. Patients with a history of drug allergy to TZDs and berberine;~15. Patients wth gestation or possible gestation or lactation, or males or females who expecting gestation during clinical trial;~16. Mental diseases patients;~17. Those who refuse to sign informed consent;~18. Any other conditions, which, in the opinion of the investigators would impede competence or compliance or possibility of hindering completion of the study;~19. Patients with serum triglyceride ≥ 5.0 mmol/L;~20. Patients with thyroid disease, including hyperthyroidism or hypothyroidism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lifestyle intervention (Type: EXPERIMENTAL): Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
- Life style intervention, pioglitazone (Type: EXPERIMENTAL): Life style intervention with pioglitazone 15mg qd for 16 weeks
- Life style intervention, berberine (Type: EXPERIMENTAL): Life style intervention with berberine 0.5g tid for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).